Portal de Periódicos da CAPES

Effectiveness of tildrakizumab 200 mg: an Italian multicenter study

2024; Informa; Volume: 35; Issue: 1 Linguagem: Inglês

10.1080/09546634.2024.2420825

1471-1753

Annunziata Dattola, Nicoletta Bernardini, Francesca Svara, Anna Balato, Giacomo Caldarola, D D’Amico, Clara De Simone, Eugenia Veronica Di Brizzi, Maria Esposito, Claudia Giofrè, Domenico Giordano, Claudio Guarneri, Francesco Loconsole, Viviana Lora, Gaia Moretta, Diego Orsini, Severino Persechino, Concetta Potenza, Simone Ragonesi, Giovanni Pellacani, Ketty Peris, Maria Concetta Fargnoli, Antonio Giovanni Richetta,

Microscopic Colitis

Psoriasis is a chronic immune-mediated disease that can be challenging to treat, especially in patients with severe disease or high body weight. Tildrakizumab is a monoclonal antibody which inhibits IL-23, approved for moderate-to-severe psoriasis with a standard 100 mg dose. A 200 mg dose may provide greater efficacy for patients over 90 kg or with high disease burden.